Describe the laboratory diagnosis and immunophenotypic classification of acute lymphoblastic leukaemia.
10 marks · directive: Describe
The core of a good answer
Acute lymphoblastic leukaemia is diagnosed by blood counts and smear showing circulating lymphoblasts, confirmed by bone marrow with typically more than 20 percent lymphoblasts, flow cytometry immunophenotyping (TdT expressed, myeloperoxidase not expressed), cytogenetics and molecular tests for prognostic lesions such as ETV6-RUNX1, BCR-ABL1 and KMT2A rearrangement, and lumbar puncture; immunophenotypically it is B-lineage ALL (CD19, CD22, CD79a; with stages such as common ALL, pre-B and mature B) in about 85 percent and T-lineage ALL (CD2, CD3, CD5, CD7) in about 15 percent.
An outline written by upsc.help, not an official UPSC answer; every fact checked by a separate review. How we work
What the question asks
Two parts: a stepwise laboratory work-up from blood count to molecular tests, and a classification by lineage and maturation stage with marker profiles. A table of markers scores well.
Answer outline
Introduction
Acute lymphoblastic leukaemia (ALL) is a malignant proliferation of immature lymphoid cells (lymphoblasts); it is the commonest childhood cancer, peaking between 3 and 7 years.
Laboratory diagnosis
- Complete blood count: anaemia and low platelets; white cell count at presentation varies widely.
- Peripheral smear: circulating lymphoblasts in the majority of cases.
- Bone marrow aspirate and biopsy: conclusive; typically more than 20 percent lymphoblasts.
- Myeloperoxidase, a myeloid marker, is typically not expressed (distinguishes from AML).
- Flow cytometry immunophenotyping: the preferred method; TdT expression helps separate malignant lymphoblasts from reactive lymphocytes.
- Cytogenetics and molecular: t(12;21) ETV6-RUNX1 (commonest specific abnormality in childhood B-ALL, good prognosis), hyperdiploidy over 50 chromosomes (good), Philadelphia chromosome BCR-ABL1 (poor, tyrosine kinase inhibitors added), KMT2A (MLL) rearrangement (most common in infants; t(4;11) poor).
- Lumbar puncture to see whether the brain and spinal column have been invaded; close monitoring for tumour lysis syndrome after starting therapy.
Immunophenotypic classification
- B-lineage ALL, about 85 percent: CD19, CD22, CD79a positive.
- Common ALL: CD10 positive (CD10 is variable in B-ALL).
- Pre-B ALL: cytoplasmic immunoglobulin positive.
- Mature B-cell ALL: surface immunoglobulin positive (Burkitt leukaemia corresponds to FAB L3).
- T-lineage ALL, about 15 percent, with male predominance: CD2, CD3, CD4, CD5, CD7, CD8 positive.
Older morphological classification (FAB)
- L1 small uniform cells; L2 large heterogeneous cells; L3 large varied cells with vacuoles; much of this classification has been abandoned because of its limited value for treatment and prognosis.
Conclusion
Morphology suggests ALL, but immunophenotyping and genetics confirm lineage, stage and risk, which together decide treatment.
Examples and data to cite
- Tyrosine kinase inhibitors are often included in the treatment of Philadelphia-positive (BCR-ABL1) ALL.
- Lumbar puncture at diagnosis shows whether the brain and spinal column have been invaded.
Facts to remember
- Bone marrow typically shows more than 20 percent leukaemic lymphoblasts.
- About 85 percent of ALL is B-lineage and 15 percent T-lineage.
- t(12;21) ETV6-RUNX1 is the most common abnormality in childhood B-ALL.
- About 75 percent of cases occur before age 6.